Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Reiss

Showing results (191-200 of 207) with videos related to

Pageof 21
Sort By:
The Journal of Clinical Investigation|December 31, 1997
Selective inhibition of syncytium-inducing and nonsyncytium-inducing HIV-1 variants in individuals receiving didanosine or zidovudine, respectivelyA B van't Wout, L J Ran, M D de Jong, et al.
HIV Medicine|March 12, 2004
Differential CD4 T-cell response in HIV-1-infected patients using protease inhibitor-based or nevirapine-based highly active antiretroviral therapyF van Leth, F W N M Wit, P Reiss, et al.
The Journal of Infectious Diseases|March 5, 2004
Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles?E Fontas, F van Leth, C A Sabin, et al.
HIV Medicine|April 25, 2006
The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D StudyM G Law, N Friis-Møller, W M El-Sadr, et al.
Physical Review Letters|October 18, 2024
Unconventional Crystal Structure of the High-Pressure Superconductor La_{3}Ni_{2}O_{7}P Puphal, P Reiss, N Enderlein, et al.
Nederlands Tijdschrift Voor Geneeskunde|September 6, 2001
[HIV-1 therapy in the Netherlands; virological and immunological response to antiretroviral therapy]M Jambroes, G J Weverling, P Reiss, et al.
Lancet (London, England)|September 6, 2003
Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studiesG Chêne, J A C Sterne, M May, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 10, 2001
A retrospective, cohort-based survey of patients using twice-daily indinavir + ritonavir combinations: pharmacokinetics, safety, and efficacyD M Burger, P W Hugen, R E Aarnoutse, et al.
HIV Medicine|August 9, 2011
Randomized comparison of metabolic and renal effects of saquinavir/r or atazanavir/r plus tenofovir/emtricitabine in treatment-naïve HIV-1-infected patientsS M E Vrouenraets, F W N M Wit, E Fernandez Garcia, et al.
HIV Medicine|February 2, 2018
Long-term effectiveness of recommended boosted protease inhibitor-based antiretroviral therapy in EuropeJ R Santos, A Cozzi-Lepri, A Phillips, et al.
Pageof 21

Showing results (191-200 of 207) with videos related to

Sort By:
Pageof 21
The Journal of Clinical Investigation|December 31, 1997
Selective inhibition of syncytium-inducing and nonsyncytium-inducing HIV-1 variants in individuals receiving didanosine or zidovudine, respectivelyA B van't Wout, L J Ran, M D de Jong, et al.
HIV Medicine|March 12, 2004
Differential CD4 T-cell response in HIV-1-infected patients using protease inhibitor-based or nevirapine-based highly active antiretroviral therapyF van Leth, F W N M Wit, P Reiss, et al.
The Journal of Infectious Diseases|March 5, 2004
Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles?E Fontas, F van Leth, C A Sabin, et al.
HIV Medicine|April 25, 2006
The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D StudyM G Law, N Friis-Møller, W M El-Sadr, et al.
Physical Review Letters|October 18, 2024
Unconventional Crystal Structure of the High-Pressure Superconductor La_{3}Ni_{2}O_{7}P Puphal, P Reiss, N Enderlein, et al.
Nederlands Tijdschrift Voor Geneeskunde|September 6, 2001
[HIV-1 therapy in the Netherlands; virological and immunological response to antiretroviral therapy]M Jambroes, G J Weverling, P Reiss, et al.
Lancet (London, England)|September 6, 2003
Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studiesG Chêne, J A C Sterne, M May, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 10, 2001
A retrospective, cohort-based survey of patients using twice-daily indinavir + ritonavir combinations: pharmacokinetics, safety, and efficacyD M Burger, P W Hugen, R E Aarnoutse, et al.
HIV Medicine|August 9, 2011
Randomized comparison of metabolic and renal effects of saquinavir/r or atazanavir/r plus tenofovir/emtricitabine in treatment-naïve HIV-1-infected patientsS M E Vrouenraets, F W N M Wit, E Fernandez Garcia, et al.
HIV Medicine|February 2, 2018
Long-term effectiveness of recommended boosted protease inhibitor-based antiretroviral therapy in EuropeJ R Santos, A Cozzi-Lepri, A Phillips, et al.
Pageof 21